Introduction
Blood platelets are produced in the bone marrow by megakaryocytes (MKs) in a process that requires extensive membrane rearrangements. During MK maturation the demarcation membrane system (DMS) forms as a surface-connected membrane extension that invaginates into the cell body and elaborates to provide membranes for future platelets. [1] [2] [3] In platelets the open canalicular system (OCS) forms multiple interconnections between cell surfaces and serves as a membrane reservoir during platelet spreading following activation. 4 The MK DMS and platelet OCS share structural similarities, but little is known about the proteins and mechanisms responsible for their formation.
Bin-Amphiphysin-Rvs (BAR) and Fes-CIP4 homology BAR (F-BAR) proteins selfassociate into dimers through coiled-coil interaction, bind negatively-charged phospholipids on the plasma membrane cytoplasmic surface and polymerize to generate tubular invaginations reminiscent of the MK DMS and platelet OCS. [5] [6] [7] [8] [9] [10] [11] The adaptor protein PACSIN2 (also called syndapin 2, FAP52) is one of the most abundant BAR/F-BAR proteins in human and mouse platelets. 12, 13 PACSIN2 has been implicated in a wide range of cellular functions including cell adhesion, spreading and migration, [14] [15] [16] [17] receptor internalization, 18, 19 and caveolae biogenesis. [20] [21] [22] PACSIN2 is composed of an N-terminal F-BAR domain, 3 central Asn-Pro-Phe motifs, which are docking sites for endocytic Eps15 homology domain proteins, 23 and a C-terminal Src homology 3 domain that interacts with actin regulatory and endocytic proteins, such as N-WASP and dynamin 2, 24,25 expression of which is required for normal MK development.
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PACSIN2 is the only BAR/F-BAR protein reported thus far to associate and/or colocalize with the cytoskeletal and scaffold protein filamin A (FlnA), [14] [15] [16] an essential regulator of platelet formation and function. 27 Heterozygous mutations in the X-linked FLNA gene in humans have been associated with altered DMS formation, giant platelets and bleeding tendency, 28, 29 and a mutation in the PRKACG gene encoding the γ regulatory subunit of protein kinase A has been associated with decreased platelet
FlnA expression and consequent macrothrombocytopenia in humans. 30 We have previously shown that MK-specific Flna deletion in mice results in severe
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From macrothrombocytopenia and prolonged bleeding due to premature release of large, fragile and poorly functional platelets. 31, 32 Here we investigated PACSIN2 expression and localization in MKs and platelets, and its regulation by FlnA.
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Methods

Platelet preparation
Immunoblot analysis
Platelets were lysed at 4°C in 1% Nonidet P-40, 150 mM NaCl, 50 mM Tris, pH 7. Biotechnology) for 2h at 4°C, followed by incubation with protein G-conjugated Sepharose beads (GE Healthcare) for 1h at 4°C. 31 Platelet lysates and immune complexes were resolved by SDS-PAGE and immunoblot analysis.
For cytoskeletal fraction studies, platelets were lysed in 0.1% Triton X-100, 60 mM PIPES, 25 mM HEPES, 10 mM EGTA and 2 mM MgCl 2 , pH 6.9, containing Complete protease inhibitor cocktail and 2 µM phalloidin (PHEM buffer). 33, 34 Cytoskeletons were isolated by centrifugation at 100,000g for 30 min at 4°C in a Beckman Optima TL ultracentrifuge (Beckman Coulter). Triton X-100 insoluble and soluble fractions were resolved by SDS-PAGE and immunoblot analysis.
PACSIN2 and FlnA constructs
GST-PACSIN2 F-BAR domain (residues 1-342), His-FlnA and EGFP-FlnA constructs were produced as described. 35, 36 GST-PACSIN2 F-BAR domain mutant P180A was generated using the QuickChange II XL site-directed mutagenesis kit (Agilent For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Technologies). Primers used were 5'-CAGCAAGGCAGATGCATCCCTCAACCC-3' (forward) and 5'-GGGTTGAGGGATGCATCTGCCTTGCTG-3' (reverse).
PACSIN2 (residues 1-486) was subcloned into MSCV with EGFP at the Cterminus using the InFusion PCR cloning kit (Clontech). Primers used were 5'-GAATTAGATCACCGGTATGTCTGTCACCTACGATGACTCT-3' (forward) and 5'-CATGGTGGCGACCGGTTTCTGGATAGCCTCGACATAGTTG-3' (reverse). MSCV-EGFP-PACSIN2 P180A was generated by site-directed mutagenesis as above. MSCV-EGFP-PACSIN2 WT and P180A were co-transfected with PCL helper plasmid into 50-70% confluent 293T cells using Fugene-6 (Roche). 37 Medium was changed 24h later, and viral supernatants were harvested at 72h. Medium was filtered (0.45
immediately or stored at -80°C.
Mapping of the FlnA-PACSIN2 interface
GST-PACSIN2 F-BAR domain WT or P180A (50 nM) was incubated with His-FlnA constructs (500 nM) for 1h at 4°C in 1% Nonidet P-40, 150 mM NaCl, 50 mM Tris, pH 7.4. 31 Complexes were pulled down by incubation with glutathione Sepharose beads (GE Healthcare). Complexes were resolved by SDS-PAGE and immunoblot analysis.
For rotary shadowing electron microscopy, GST-PACSIN2 F-BAR domain and/or HisFlnA were sprayed on mica in 50% glycerol, dried under vacuum, and metal cast with 1 nm of platinum at 6° with rotation and 3.5 nm of carbon at 90° without rotation.
Membrane tubulation assay
Liposomes were formed using equal parts of phosphatidylcholine (PC) and phosphatidylserine (PS) or phosphatidylinositol (PI) (Sigma-Aldrich). Lipids were mixed at 10 mg/ml in chloroform, and solvent evaporated under nitrogen on ice and then dried under vacuum for 30 min. Lipids were hydrated in 0.25 M sucrose at 50°C for 2h. The solution was clarified by centrifugation at 10,000g for 10 min and stored at -20°C.
Thawed lipids were diluted to 0.2 mg/ml in PBS in the presence or absence of GST-PACSIN2 F-BAR domain WT or P180A, His-FlnA or EGFP-FlnA constructs. Tubulation capacity was assessed in the electron microscope after negative staining of proteinliposomes solutions with 1% uranyl acetate or in a fluorescent microscope. 
Mouse bone marrow MK preparation and retroviral production
Mouse bone marrow MKs were prepared as described. 26, 39 Flushed bone marrow cells were cultured in 2.6% serum-supplemented StemPro-34 medium (Gibco) with 2 mM Lglutamine, penicillin/streptomycin, and 50 ng/ml recombinant stem cell factor (SCF; R&D Systems) for 2 days. Cells were cultured for 2 days in the presence of 50 ng/ml SCF and 50 ng/ml recombinant thrombopoietin (TPO; R&D Systems), and for 2 days in Cells were then cultured in fresh media and TPO for 2 days before isolation of advanced MKs over a BSA step-gradient for further analysis. Mature MKs were fixed in 4% paraformaldehyde and centrifuged onto poly-L-lysine-coated coverslips. For SIM imaging experiments WT mouse MKs were cultured and prepared according to methods previously described, 38 where MKs were cultured on Matrigel and then fixed and stained without being cytospun on coverslips.
Transmission electron microscopy
Bone marrow cells were obtained by flushing mouse femurs with 2.5% glutaraldehyde in PBS; after overnight fixation they were post-fixed with 2% osmium tetroxide in H2O for 1h and dehydrated in a graded acetone series before embedding in Epon-Araldite. Thin sections were cut and stained with uranyl acetate and lead citrate. Grids were examined with a JEOL JEM-1011 electron microscope at 80 kV. Images were captured with a side-mounted Advantage HR CCD camera (Advanced Microscopy Techniques).
26,38
Statistical analysis
All experiments were performed at least in triplicate. Results were analyzed with Student t test using the Prism software (GraphPad). Differences were considered significant when P < 0.05.
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Results
PACSIN2 expression in platelets
Human and mouse platelet lysates were subjected to SDS-PAGE and probed for PACSIN2 ( Figure 1A ). PACSIN2 was detected as a single band of 65 kDa in human and mouse platelets, indicating that platelets expressed the long PACSIN2 isoform of 486 residues, but not its shorter splicing variant of 445 residues and 52 kDa. 18, 40 The amount of PACSIN2 molecules in mouse platelets was determined by densitometric analysis of immunoblots using GST-PACSIN2 full-length as standard ( Figure 1B ).
Control mouse platelets contained 7.45 x 10 −21 mol PACSIN2, or 2,200 PACSIN2 dimers, consistent with previous estimation.
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PACSIN2 associates with FlnA in platelets
PACSIN2 associates and/or colocalizes with FlnA in chicken fibroblasts, Xenopus XTC cells and human carcinoma cells. [14] [15] [16] Their interaction was therefore investigated in human platelets, both resting and activated with 10 µg/ml of the collagen-related peptide (CRP) for 2 min. Platelets were lysed and PACSIN2 and FlnA were immunoprecipitated, subjected to SDS-PAGE and probed for FlnA ( Figure 1C ). Both resting and CRPactivated platelet PACSIN2 pulled-down FlnA, detected as a band of 280 kDa.
Mouse platelets were activated with 1 U/ml thrombin for 2 min and lysed in PHEM buffer. Triton X-100 high-speed soluble (HSS) and pellet (HSP) fractions were collected by centrifugation of platelet lysates at 100,000g, subjected to SDS-PAGE and probed for PACSIN2 and FlnA. About half of FlnA associated with F-actin, the HSP phase ( Figure 1D ). PACSIN2 remained in the HSS phase in resting and thrombin-stimulated platelets, indicating that, although PACSIN2 associated with FlnA, it failed to cosediment with the platelet actin cytoskeleton.
Mapping of the PACSIN2 binding site on FlnA
The FlnA-PACSIN2 interface was mapped in vitro using recombinant proteins ( Figure   2 ). FlnA is composed of an N-terminal tandem calponin-homology actin-binding domain (ABD), followed by 24 immunoglobulin-like repeats, which are structurally separated into a linear rod 1 (repeats 1-15), a compact rod 2 (repeats [16] [17] [18] [19] [20] [21] [22] [23] , and a C-terminal self- Figure 2B ). Dimeric FlnA molecules are 160 nm in length, 36 and PACSIN2 F-BAR domains self-assemble into unique S-shaped dimers, ~20 nm in length, [43] [44] [45] [46] [47] Table 1 ). The presence of full-length FlnA tripled the number of elongated structures found in negatively-stained samples and increased the tubule diameter to 77 ± 27 nm (mean ± SD; range 36-150 nm; n = 177; P < 0.0001), although a wide distribution was observed and FlnA modestly affected the tubule length. As control, FlnA alone did not promote tubule formation (Table 1) .
GST-PACSIN2 F-BAR mutant P180A generated tubules comparable to those of GST-PACSIN2 F-BAR WT ( Figure 3A ; Table 1 ), indicating that the substitution did not affect tip-to-tip interaction and membrane tubulation. However, FlnA failed to enhance membrane tubulation generated by GST-PACSIN2 F-BAR mutant P180A, indicating that FlnA binding to PACSIN2 F-BAR domain was necessary to enhance tubule formation.
Experiments to determine whether FlnA was bound along the tubules generated by GST-PACSIN2 F-BAR domain were routinely negative (data not shown), suggesting that FlnA could no longer bind PACSIN2 once the F-BAR domain dimers polymerized 
PACSIN2 localization in platelets requires FlnA
Examination by super-resolution SIM showed that PACSIN2 localization in Flna fl/fl Pf4-Cre (Flna-null) platelets differed from that observed in control Flna fl/fl platelets ( Figure   5A ; Video 1). While most WT platelets had a single PACSIN2 focus, the largest group of Flna-null platelets had no definite focus, and many had 3 or more foci ( Figure 5B ; Video 2), which was not seen in normal cells. These foci were in apparent contact with the plasma membrane, here labeled for GPIbα (Figure 5A ,B; Videos 1,2).
Flna-null platelets contained 15.6 x 10 −21 mol PACSIN2, or 4,700 PACSIN2 dimers ( Figure 1B) , a 2.1-fold increase compared to control platelets, consistent with the previously reported increased volume of Flna-null platelets. 31, 32 PACSIN2 expression levels in Flna-null MKs were similar to those of control MKs (data not shown).
PACSIN2 localization in MKs requires FlnA binding
We analyzed the distribution of PACSIN2 in WT cultured mouse bone marrow MKs by SIM ( Figure 6 ). In mid-stage MKs, PACSIN2 was confined mostly to a single locus, Consistent with this hypothesis, we observed DMS and platelet territories in freshly isolated mature Flna-null MKs to be less well defined than in WT MKs, paralleling observations in patients with FLNA mutations. 28 The dispersed localization of PACSIN2 observed in mature MKs suggests that it is no longer involved in the formation of tubular structures after the DMS is formed.
However, as with MKs, the presence of FlnA appears to be required for targeting of PACSIN2 within platelets, since microscopic examination shows PACSIN2 to be limited to 1-2 distinct caveolae-like foci in human and WT mouse platelets, while Flna-null mouse platelets had indeterminate or multiple foci. While the precise function of these PACSIN2 foci remains to be determined, their localization near the platelet plasma The FlnA-binding site is located near PACSIN2 residues 184-187, which are necessary for tip-to-tip interaction and membrane tubulation. 47 Experiments to determine whether FlnA was bound along membrane tubules were routinely negative, suggesting that FlnA molecules initially bind to PACSIN2 F-BAR domains to catalyze membrane tubulation, but dissociate from PACSIN2 once membrane tubules elongate.
This would account for our observations that: 1) FlnA was not found on maximally MKs. Areas within boxes in micrographs A1 and B1 are shown at higher magnification in panels A2 and B2, respectively. Scale bars represent 2 µm at 5000x magnification (top), and 500 nm at 15000x magnification (bottom). 
